N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.

doi:10.1016/j.cell.2021.03.028

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.

Cell - 29 Apr 2021

McCallum Matthew, De Marco Anna, Lempp Florian A, Tortorici M Alejandra, Pinto Dora, Walls Alexandra C, Beltramello Martina, Chen Alex, Liu Zhuoming, Zatta Fabrizia, Zepeda Samantha, di Iulio Julia, Bowen John E, Montiel-Ruiz Martin, Zhou Jiayi, Rosen Laura E, Bianchi Siro, Guarino Barbara, Fregni Chiara Silacci, Abdelnabi Rana, Foo Shi-Yan Caroline, Rothlauf Paul W, Bloyet Louis-Marie, Benigni Fabio, Cameroni Elisabetta, Neyts Johan, Riva Agostino, Snell Gyorgy, Telenti Amalio, Whelan Sean P J, Virgin Herbert W, Corti Davide, Pizzuto Matteo Samuele, Veesler David

Abstract excerpt

The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-binding domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient plasma. Little is known about neutralizing Abs binding to epitopes outside the RBD and their contribution to protection. Here, we describe 41 human monoclonal Abs (mAbs) derived from memory B cells, which recognize the SARS-CoV-2 S N-terminal domain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, Viral

Share to COVID-19

Share to Cricetinae

Share to Epitope Mapping

Share to Neutralization Tests

Share to Protein Domains

Share to SARS-CoV-2

Source

Open in PubMed Open full text

Identifiers

PMID: 33761326
DOI: 10.1016/j.cell.2021.03.028
PMCID: PMC7962585

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.PMID 33761326Read ↗

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2Semantic proximity Read ↗

A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protectionSemantic proximity Read ↗

Characteristics and functions of infection-enhancing antibodies to the N-terminal domain of SARS-CoV-2Semantic proximity Read ↗

Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variantsSemantic proximity Read ↗

Prolonged evolution of the human B cell response to SARS-CoV-2 infectionSemantic proximity Read ↗

Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteinsSemantic proximity Read ↗

The antigenic anatomy of SARS-CoV-2 receptor binding domainSemantic proximity Read ↗

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.Semantic proximity Read ↗

Characterization of neutralizing antibodies from a SARS-CoV-2 infected individualSemantic proximity Read ↗

Epitope-Driven Polyfunctional Divergence of SARS-CoV-2 RBD AntibodiesSemantic proximity Read ↗

Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infectionSemantic proximity Read ↗

High seroreactivity against SARS-CoV-2 Spike epitopes in a pre SARS-CoV-2 cohort: implications for antibody testing and vaccine designSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.